Shraddha Thakkar,William Slikker Jr,Frank Yiannas,Primal Silva,Burton Blais,Kern Rei Chng,Zhichao Liu,Alok Adholeya,Francesco Pappalardo,Mônica da Luz Carvalho Soares,Patrick E Beeler,Maurice Whelan,Ruth Roberts,Jurgen Borlak,Martha Hugas,Carlos Torrecilla-Salinas,Philippe Girard,Matthew C Diamond,Didier Verloo,Binay Panda,Miquella C Rose,Joaquim Berenguer Jornet,Ayako Furuhama,Hong Fang,Ernest Kwegyir-Afful,Kasey Heintz,Kirk Arvidson,Juan Garcia Burgos,Alexander Horst,Weida Tong

Abstract:In 2013, the Global Coalition for Regulatory Science Research (GCRSR) was established with members from over ten countries (www.gcrsr.net). One of the main objectives of GCRSR is to facilitate communication among global regulators on the rise of new technologies with regulatory applications through the annual conference Global Summit on Regulatory Science (GSRS). The 11th annual GSRS conference (GSRS21) focused on "Regulatory Sciences for Food/Drug Safety with Real-World Data (RWD) and Artificial Intelligence (AI)." The conference discussed current advancements in both AI and RWD approaches with a specific emphasis on how they impact regulatory sciences and how regulatory agencies across the globe are pursuing the adaptation and oversight of these technologies. There were presentations from Brazil, Canada, India, Italy, Japan, Germany, Switzerland, Singapore, the United Kingdom, and the United States. These presentations highlighted how various agencies are moving forward with these technologies by either improving the agencies' operation and/or preparing regulatory mechanisms to approve the products containing these innovations. To increase the content and discussion, the GSRS21 hosted two debate sessions on the question of "Is Regulatory Science Ready for AI?" and a workshop to showcase the analytical data tools that global regulatory agencies have been using and/or plan to apply to regulatory science. Several key topics were highlighted and discussed during the conference, such as the capabilities of AI and RWD to assist regulatory science policies for drug and food safety, the readiness of AI and data science to provide solutions for regulatory science. Discussions highlighted the need for a constant effort to evaluate emerging technologies for fit-for-purpose regulatory applications. The annual GSRS conferences offer a unique platform to facilitate discussion and collaboration across regulatory agencies, modernizing regulatory approaches, and harmonizing efforts.

Supporting a data-driven approach to regulatory intelligence

Artificial Intelligence In Drug Regulatory Submissions In India

Big Data: transforming drug development and health policy decision making

Seeing the whole elephant: integrated advanced data analytics in support of RWE for the development and use of innovative pharmaceuticals

Artificial intelligence and real-world data for drug and food safety - A regulatory science perspective

Trust but Verify: Lessons Learned for the Application of AI to Case-Based Clinical Decision-Making From Postmarketing Drug Safety Assessment at the US Food and Drug Administration

Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model

Transparency, reproducibility, and replicability of pharmacoepidemiology studies in a distributed network environment

Contemporary Practice and Considerations for Real-World Data Source Identification and Feasibility Assessment

Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration

Applications of artificial intelligence in drug development using real-world data

Use of big data for drug development and for public and personal health and care

ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products

Potential Use of Artificial Intelligence for Regulatory Intelligence: Biopharmaceutical Industry’s Views

Digital Research Environment(DRE)-enabled Artificial Intelligence (AI) to facilitate early stage drug development

Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory Submission

Voluntary Exploratory Data Submissions to the Us Fda and the Ema: Experience and Impact

Using Social Media as a Source of Real-World Data for Pharmaceutical Drug Development and Regulatory Decision Making

Advancing structured decision‐making in drug regulation at the FDA and EMA

Application of advanced in silico methods for predictive modeling and information integration

Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions